Loading…
Edesa Biotech, Inc. is projected to decline to $5.05 by 2027, a -3% move from its current price of $5.23. EDSA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $4.96 | $5.23 | $5.51 | -0.10% |
| Aug 6 | $4.85 | $5.22 | $5.62 | -0.19% |
| Aug 7 | $4.76 | $5.22 | $5.71 | -0.29% |
| Aug 8 | $4.69 | $5.21 | $5.78 | -0.38% |
| Aug 9 | $4.63 | $5.21 | $5.85 | -0.47% |
| Aug 10 | $4.58 | $5.20 | $5.91 | -0.57% |
| Aug 11 | $4.52 | $5.20 | $5.97 | -0.66% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.52 | $5.20 | $5.97 | -0.66% |
| Week 2 | $4.24 | $5.16 | $6.27 | -1.32% |
| Week 3 | $4.04 | $5.13 | $6.51 | -1.98% |
| Week 4 | $3.86 | $5.09 | $6.71 | -2.63% |
| Week 5 | $3.71 | $5.06 | $6.89 | -3.27% |
| Week 6 | $3.58 | $5.03 | $7.05 | -3.92% |
| Week 7 | $3.46 | $4.99 | $7.19 | -4.55% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody in Phase 3 for acute respiratory distress syndrome; and EB01, a topical vanishing cream containing a non-steroidal anti-inflammatory compound that has completed Phase 3 to treat chronic allergic contact dermatitis.
The company also develops EB07, a monoclonal antibody in Phase 2 for pulmonary fibrosis, and EB06, a human monoclonal antibody candidate that binds to CXCL10 and inhibits its interaction with CXCR3A and CXCR3B. It has collaboration agreements with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10, and with Yissum Research Development Company for therapeutic and dermatologic applications. The company was founded in 2015 and is headquartered in Markham, Canada, in the Healthcare sector.
Edesa Biotech operates within the healthcare space, leveraging its portfolio of monoclonal antibodies and topical formulations to address inflammatory and immune-related conditions.
Edesa Biotech, Inc. (EDSA) is a healthcare stock currently priced at $5.25 with a market capitalization of $50.57M and a market rank of 4318. The stock trades in a space focused on inflammatory and immune-related diseases, with a portfolio including EB05, EB01, EB07, and EB06.
The near-term technical picture shows a neutral stance, with a 30-day range from $3.64 to $7.57 and a nearby support of $5.21 and resistance at $8.19. The current sentiment is NEUTRAL and the RSI is 40, with SMA50 at $7.81 and SMA200 at $4.84, reflecting a stock that is trading around its near-term range amid elevated volatility (annualized volatility 100%).
Forecasts project a path from a neutral near term toward longer-term upside, with 2026 showing an average price of $5.25 and a 0 ROI, followed by a sequence of rising averages and bullish sentiment into 2030 and beyond, including a 2030 average of $8.15 and a 55.3 ROI and a 2050 average of $22.62 with a 330.8 ROI.
A major floor 45.1% below — a decisive break under it would weaken the trend.
The nearest floor, 5.0% below — buyers have tended to step in here.
The nearest ceiling, 56.6% above — a clean break opens room to run.
A major ceiling 249.5% above — clearing it would confirm fresh momentum.
Key EDSA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of EDSA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.21 | Buy | $5.26 | Sell |
| MA 10 | $5.45 | Sell | $5.53 | Sell |
| MA 20 | $6.20 | Sell | $6.02 | Sell |
| MA 50 | $6.89 | Sell | $6.92 | Sell |
| MA 100 | $8.02 | Sell | $6.82 | Sell |
| MA 200 | $4.91 | Buy | $5.72 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 34.90 | Neutral |
| Stoch RSI (14) | 27.67 | Neutral |
| CCI (20) | -96.49 | Neutral |
| Williams %R (14) | -92.63 | Info |
| MACD (12,26,9) | -0.07 | Sell |
| ROC (12) | -25.62 | Sell |
| Bollinger %B (20,2) | 0.16 | Neutral |
| Stochastic %K (14) | 7.37 | Buy |
| TRIX (15) | -1.09 | Sell |
| Awesome (5,34) | -1.42 | Sell |
| Ultimate (7,14,28) | 30.78 | Neutral |
| Momentum (10) | -1.49 | Sell |
| Aroon Osc (25) | -84.00 | Sell |
| Hull MA (9) | 5.10 | Buy |
| ADX (14) | 21.37 | Sell |
| ATR (14) | 0.31 | Info |
The 30-day technical picture is NEUTRAL. The RSI(14) is 40, suggesting modest downside momentum relative to overbought/oversold extremes. The stock trades around the SMA50 at $7.81 and above the SMA200 at $4.84, indicating mixed near-term momentum.
The 30-day price range spans from $3.64 to $7.57, with support at $5.21 and resistance at $8.19. This setup implies potential for range-bound movement near the $5 level, with upside room toward the $8.19 resistance if momentum improves. Overall, volatility remains a key feature, reflected in an annualized volatility of 100%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.80 | $5.23 | $6.49 | 0% | Neutral | |
| $3.70 | $5.05 | $7.46 | -3% | Neutral | |
| $3.21 | $4.66 | $7.34 | -11% | Neutral | |
| $3.60 | $5.49 | $9.07 | +5% | Neutral | |
| $4.47 | $7.15 | $12.30 | +37% | Bullish | |
| $4.06 | $6.78 | $12.07 | +30% | Bullish | |
| $3.98 | $6.91 | $12.67 | +32% | Bullish | |
| $3.54 | $6.41 | $12.07 | +22% | Bullish | |
| $2.79 | $5.24 | $10.12 | 0% | Neutral | |
| $3.93 | $7.67 | $15.16 | +47% | Bullish | |
| $3.59 | $7.97 | $17.29 | +52% | Bullish | |
| $7.89 | $17.53 | $40.33 | +235% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.80 | $5.23 | $6.45 | +0.00% |
| September 2026 | $4.30 | $5.21 | $6.60 | -0.30% |
| October 2026 | $3.90 | $4.80 | $6.19 | -8.04% |
| November 2026 | $3.69 | $4.59 | $6.03 | -4.21% |
| December 2026 | $3.88 | $4.88 | $6.49 | +6.18% |
Click any year to see its month-by-month EDSA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect EDSA to range from $0.80 to $6.49 through 2026. The $5.23 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The EDSA price prediction for 2027 points to an average of $5.05 (low $3.70, high $7.46) — a potential decline of -3% on today's $5.23. A consolidation phase looks the most probable path here.
In 2028, EDSA is projected to trade between $3.21 and $7.34, averaging $4.66 — a potential decline of -11% from today's $5.23. That is -8% versus the projected 2027 average. Price action looks broadly range-bound.
Edesa Biotech, Inc.'s 2029 outlook centres on $5.49, within a $3.60 to $9.07 range. That is up +18% on the projected 2028 average. That marks a +5% change versus current levels. A consolidation phase looks the most probable path here.
By 2030, EDSA could reach as high as $12.30, with a base case around $7.15 and support toward $4.47 — roughly +37% from $5.23. Momentum favours further upside here.
Expect EDSA to range from $4.06 to $12.07 through 2031. The $6.78 average target implies a +30% move from current prices. That is -5% versus the projected 2030 average. Buyers look set to stay in control over this stretch.
The EDSA price prediction for 2032 points to an average of $6.91 (low $3.98, high $12.67) — a potential gain of +32% on today's $5.23. Momentum favours further upside here.
In 2033, EDSA is projected to trade between $3.54 and $12.07, averaging $6.41 — a potential gain of +22% from today's $5.23. That is -7% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
Edesa Biotech, Inc.'s 2034 outlook centres on $5.24, within a $2.79 to $10.12 range. That is -18% versus the projected 2033 average. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2035, EDSA could reach as high as $15.16, with a base case around $7.67 and support toward $3.93 — roughly +47% from $5.23. Buyers look set to stay in control over this stretch.
Expect EDSA to range from $3.59 to $17.29 through 2040. The $7.97 average target implies a +52% move from current prices. That is up +4% on the projected 2035 average. Momentum favours further upside here.
The EDSA price prediction for 2050 points to an average of $17.53 (low $7.89, high $40.33) — a potential gain of +235% on today's $5.23. Buyers look set to stay in control over this stretch.
Investing $1,000 in EDSA today (≈ 191.204589 EDSA) could be worth
$3,352.46
+$2,352.46 (+235%) by 2050 · US Dollar
Based on the average projected EDSA price of $17.53 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in EDSAwould be worth at today's price.
$1,000 invested in EDSA on Jul 31, 2025 (≈ 444.444444 EDSA) would be worth
$2,324.44
+$1,324.44 (+132.4%) today · 2.32× · US Dollar
Based on a EDSA entry price of $2.25 vs. today's $5.23.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $5.25 | $996.19 | -0.4% |
| 1 month ago | $7.75 | $674.84 | -32.5% |
| 3 months ago | $17.59 | $297.33 | -70.3% |
| 6 months ago | $1.23 | $4,252.03 | +325.2% |
| 1 year ago | $2.25 | $2,324.44 | +132.4% |
| All time (5.0y) ago | $33.95 | $154.05 | -84.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our EDSA forecast.
Our base-case forecast reaches $10.00 around 2050.
Implied market cap at $10.00: $96.33M
The multi-year forecast turns bullish in the later years, with a progression from neutral to upside potential. In 2026, the average price is projected at $5.25 with a min of $0.80 and a max of $6.71, and a forecast ROI of 0, with a NEUTRAL sentiment.
In 2029 the outlook improves to a bullish stance, with a min of $4.27, an average of $6.57, a max of $10.94 and a forecast ROI of 25.2. The pattern continues into 2030 with an average of $8.15 and a max of $14.13, yielding a 55.3 ROI, and a 2031–2034 cluster remaining bullish with averages around $7.85 to $7.90 and ROIs between 36.6 and 50.4.
By 2035 the forecast shows a notable rise, with a min of $5.07, an average of $10.05, a max of $20.07 and a high ROI of 91.5, continuing the bullish trajectory into 2040 (avg $9.92, ROI 88.9) and culminating in 2050 (avg $22.62, max $52.02, ROI 330.8). Across these years, the sentiment remains BULLISH, signaling meaningful upside potential alongside downside risk in the near term.
Overall, the long horizon envisions a steady to strong appreciation from mid-to-late decade into 2050, with bullish sentiment dominating the forecast and outsized upside in the far future. Investors should note the variability in near-term results and the sensitivity of outcomes to evolving clinical and regulatory dynamics, as indicated by the year-by-year ranges and ROIs.
Tap a question to reveal the answer.
For 2030, the forecast shows an average price of $8.15, with a min of $5.05, a max of $14.13, and a forecast ROI of 55.3. The sentiment is BULLISH.
Forecasts show a neutral stance in 2026 with an average price of $5.25 and ROI 0, followed by rising values and bullish sentiment later, including a 2030 average of $8.15 (ROI 55.3) and a 2050 average of $22.62 (ROI 330.8). These are estimates and not guarantees.
Yes. The 2035 forecast shows a max of $20.07, with the 2035 average at $10.05 and a bullish sentiment. The long-run outlook also shows higher potential, including a 2050 max of $52.02.
The current price is $5.25 and the market cap is $50.57M.
The 30-day range is $3.64 to $7.57, with support at $5.21 and resistance at $8.19.
Edesa Biotech, Inc. Community Discussion
0Share your Edesa Biotech, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.